Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis

International Journal of Oncology

Volumn 35, Issue 3, 2009, Pages 477-483

  Kanda, Mitsuro ^a   Nomoto, Shuji ^a   Okamura, Yukiyasu ^a   Nishikawa, Yoko ^a   Sugimoto, Hiroyuki ^a   Kanazumi, Naohito ^a   Takeda, Shin ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Methylation; MT1G; SNP chip array

Indexed keywords

METALLOTHIONEIN I; METALLOTHIONEIN IG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME 16Q; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; LIVER CELL CARCINOMA; MALE; METHYLATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; METALLOTHIONEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 70349145866     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000359     Document Type: Article

References (40)

1. Lau WY and Lai EC: Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7: 237-257, 2008.
2. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
3. Yu MC and Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127: 72-78, 2004.
4. Cusnir M and Patt YZ: Novel systemic therapy options for hepatocellular carcinoma. Cancer J 10: 97-103, 2004.
5. Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai Z, Shi GM, Wang XY, Ke AW, Wu B and Fan J: Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 68: 9167-9175, 2008.
6. Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, Carafa V, Terracciano L, Hudolin T, Spagnoli GC and Tornillo L: NY-ESO-1/ LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 115: 960-966, 2005.
7. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Shirane M, Muto T and Nagawa H: Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 66: 3370-3374, 2006.
8. Ness SA: Microarray analysis: basic strategies for successful experiments. Mol Biotechnol 36: 205-219, 2007.
9. Boguski MS and McIntosh MW: Biomedical informatics for proteomics. Nature 422: 233-237, 2003.
10. Liu X, Wang L, Zhang S, Lin J, Zhang S, Feitelson MA, Gao H and Zhu M: Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis 29: 1207-1214, 2008.
11. Tannapfel A, Anhalt K, Hausermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J and Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 201: 238-249, 2003.
12. Dutt A and Beroukhim R: Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 19: 43-49, 2007.
13. Grant SF and Hakonarson H: Microarray technology and applications in the arena of genome-wide association. Clin Chem 54: 1116-1124, 2008.
14. Lips EH, Dierssen JWF, Eijk R, Oosting J, Eilers PHC, Tollenaar R, Graaf EJ, Slot R, Wijmenga C, Morreau H and Wezel T: Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays. Cancer Res 65: 10188-10191, 2005.
15. Nomoto S, Yamashita K, Koshikawa K, Nakao A and Sidransky D: Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 8: 481-487, 2002.
16. Taira S and Yokoyama K: Self-assembly DNA-conjugated polymer for detection of single nucleotide polymorphism. Biotechnol Bioeng 88: 35-41, 2004.
17. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003.
18. Theocharis SE, Margeli AP and Koutselinis A: Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 18: 162-169, 2003.
19. Theocharis SE, Margeli AP, Klijanienko JT and Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology 45: 103-118, 2004.
20. Somji S, Sens MA, Lamm DL, Garrett SH and Sens DA: Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 25: 62-75, 2001.
21. Simpkins CO: Metallothionein in human disease. Cell Mol Biol 46: 465-488, 2000.
22. Nordberg M and Nordberg GF: Toxicological aspects of metallothionein. Cell Mol Biol 46: 451-463, 2000.
23. Ren XY, Zhou Y, Zhang JP, Feng WH and Jiao BH: Metallothionein gene expression under different time in testicular Sertoli and spermatogenic cells of rats treated with cadmium. Reprod Toxicol 17: 219-227, 2003.
24. Cai L, Satoh M, Tohyama C and Cherian MG: Metallothionein in radiation exposure: its induction and protective role. Toxicology 132: 85-98, 1999.
25. Ghoshal K and Jacob ST: Regulation of metallothionein gene expression. Prog Nucleic Acid Res Mol Biol 66: 357-384, 2001.
26. Maret W and Vallee BL: Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci USA 95: 3478-3482, 1998.
27. Gutiérrez-Reyes EY, Albores A and Ríos C: Increase of striatal dopamine release by cadmium in nursing rats and its prevention by dexamethasone-induced metallothionein. Toxicology 131: 145-154, 1998.
28. Joshi B, Ordonez-Ercan D, Dasgupta P and Chellappan S: Induction of human metallothionein 1G promoter by VEGF and heavy metals: differential involvement of E2F and metal transcription factors. Oncogene 24: 2204-2217, 2005.
29. Kumar A, Chatopadhyay T, Raziuddin M and Ralhan R: Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer 120: 230-242, 2007.
30. Stenram U, Ohlsson B and Tranberg KG. Immunohistochemical expression of metallothionein in resected hepatic primary tumors and colorectal carcinoma metastases. APMIS 107: 420-424, 1999.
31. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N and Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol 21: 341-347, 2006.
32. Huang Y, de la Chapelle A and Pellegata NS: Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104: 735-744, 2003.
33. Roth MJ, Abnet CC, Hu N, Wang QH, Wei WQ, Green L, D'Alelio M, Qiao YL, Dawsey SM, Taylor PR and Woodson K: p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep 15: 1591-1597, 2006.
34. Henrique R, Jeronimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C and Sidransky D: MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 14: 1274-1278, 2005.
35. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST and Ghoshal K: Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 67: 2736-2746, 2007.
36. Ghoshal K, Majumder S, Li Z, Dong X and Jacob ST: Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J Biol Chem 275: 539-547, 2000.
37. Lau WY, Lai PB and Leung MF: Differential gene expression of hepatocellular carcinoma using cDNA microarray analysis. Oncol Res 12: 59-69, 2000.
38. Midorikawa Y, Makuuchi M, Tang W and Aburatani H: Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 13: 1487-1492, 2007.
39. Iizuka N, Hamamoto Y, Tsunedomi R and Oka M: Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci 99: 659-665, 2008.
40. Zhang LH and Ji JF: Molecular profiling of hepatocellular carcinomas by cDNA microarray. World J Gastroenterol 11: 463-468, 2005.